This segment focuses on the research and development of novel immunotherapies to treat autoimmune diseases. Statera Biopharma leverages its proprietary platform to rebalance the immune system and restore homeostasis. Research and development activities include preclinical studies, clinical trials (e.g., STAT-201 for Crohn's disease), and the development of antigen-specific killer T-cells and antibodies. The company utilizes advanced biotechnology and immunological techniques to target specific immune responses. The goal is to improve patient outcomes by reducing inflammation and disease progression. Market positioning involves targeting unmet medical needs in autoimmune disorders, with a competitive advantage in its unique approach to immune system modulation. Future opportunities include expanding into new autoimmune indications like fibromyalgia and multiple sclerosis. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships and collaborations may be formed with research institutions and pharmaceutical companies to accelerate development and commercialization.

This segment is dedicated to developing immunotherapies for various cancers. Statera Biopharma's approach involves eliciting a direct response from antigen-specific killer T-cells and antibodies to activate essential immune defenses against cancer. Research and development efforts include preclinical studies, clinical trials (e.g., STAT-401 for pancreatic cancer), and the exploration of novel therapeutic targets. The company utilizes advanced immunological techniques and potentially collaborates with other companies to develop and test new cancer treatments. The focus is on improving patient outcomes by harnessing the body's immune system to fight cancer cells. Market positioning involves targeting unmet needs in cancer treatment, with a competitive advantage in its unique immunotherapy platform. Future opportunities include expanding into other cancer types and developing combination therapies. Regulatory and clinical aspects involve obtaining FDA approvals and conducting clinical trials. Partnerships and collaborations may be formed with oncology research centers and pharmaceutical companies to accelerate development and commercialization.

This segment focuses on developing immunotherapies to combat emerging viruses and infectious diseases, including COVID-19 (STAT-205). Statera Biopharma's research and development activities include preclinical studies, clinical trials, and the development of therapies designed to elicit a direct immune response. The company leverages its proprietary platform to rebalance the immune system and restore homeostasis, utilizing advanced biotechnology and immunological techniques. The goal is to improve patient outcomes by providing effective treatments for viral infections. Market positioning involves addressing unmet medical needs in infectious diseases, with a competitive advantage in its unique immunotherapy platform. Future opportunities include expanding into other viral threats and developing preventative therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships and collaborations may be formed with research institutions and pharmaceutical companies to accelerate development and commercialization.